

Phase Ib/II single-arm trial evaluating the combination  
capecitabine for the treatment of HER2-positive breast  
(TRIO-US B-09)

Therapeutic Advances in Medical Oncology

10, 175883591880733

DOI: 10.1177/1758835918807339

Citation Report

#	ARTICLE	IF	CITATIONS
1	Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 401-408.	1.1	18
2	Neratinib Plus Capecitabine Provides a Glimmer of Hope for a Daunting Disease. <i>Journal of Clinical Oncology</i> , 2019, 37, 1044-1046.	0.8	0
3	The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases. <i>Clinical Cancer Research</i> , 2019, 25, 3374-3383.	3.2	57
4	Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382096214.	0.8	12
5	The Functional Role of Voltage-Gated Sodium Channel Nav1.5 in Metastatic Breast Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 1111.	1.6	22
6	Landscape of combination therapy trials in breast cancer brain metastasis. <i>International Journal of Cancer</i> , 2020, 147, 1939-1952.	2.3	31
7	Molecular Mechanisms Associated with Brain Metastases in HER2-Positive and Triple Negative Breast Cancers. <i>Cancers</i> , 2021, 13, 4137.	1.7	22
8	Targeted Therapies for Breast Cancer Brain Metastases. <i>Clinical Breast Cancer</i> , 2021, 21, 263-270.	1.1	3
9	HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa136.	0.4	6
10	Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem. , 2020, 3, 179-198.		11
11	The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience. <i>Journal of Modern Oncology</i> , 2019, 21, 17-24.	0.1	1
12	<i>Neuroonkologie.</i> , 2020, , 257-271.		0
13	Targeting the Key Signaling Pathways in Breast Cancer Treatment Using Natural Agents. , 2020, , 137-183.		2
15	Global management of brain metastasis from renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103600.	2.0	2
16	Treatment of breast cancer brain metastases: radiotherapy and emerging preclinical approaches. , 0, , 23-36.		10
17	Breast cancer brain metastasis: Current evidence and future directions. <i>Cancer Medicine</i> , 2023, 12, 1007-1024.	1.3	18
18	Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
19	Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. <i>Cancers</i> , 2022, 14, 4543.	1.7	9

#	ARTICLE	IF	CITATIONS
20	Advances in the Management of Central Nervous System Metastases from Breast Cancer. International Journal of Molecular Sciences, 2022, 23, 12525.	1.8	1
21	Anti-Hormonal Therapy in Breast Cancer and Its Effect on the Blood-Brain Barrier. Cancers, 2022, 14, 5132.	1.7	2
22	Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer. Cancers, 2022, 14, 5136.	1.7	0
23	Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis. Cancers, 2022, 14, 5612.	1.7	1
24	Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases. CNS Drugs, 0, , .	2.7	4
25	Systemic treatments for breast cancer brain metastasis. Frontiers in Oncology, 0, 12, .	1.3	0